Quantum BioPharma Ltd.
QNTM
$3.02
-$0.34-9.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.61% | 21.78% | 71.89% | -18.09% | 25.49% |
| Depreciation & Amortization | 14.72% | 20.28% | 3.36% | 7.99% | -7.69% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.97% | 11.89% | 40.41% | 50.50% | 298.82% |
| Operating Income | 61.97% | -11.89% | -40.41% | -50.50% | -298.82% |
| Income Before Tax | 32.13% | -18.24% | -191.31% | -317.90% | -230.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.13% | -18.24% | -191.31% | -317.90% | -230.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 604.79% | -403.61% | 113.34% | -13.24% | -62.65% |
| Net Income | 43.54% | -38.98% | -197.35% | -350.60% | -284.39% |
| EBIT | 61.97% | -11.89% | -40.41% | -50.50% | -298.82% |
| EBITDA | 63.38% | -11.64% | -41.94% | -52.90% | -324.79% |
| EPS Basic | 70.80% | 66.44% | 36.89% | -11.07% | -17.46% |
| Normalized Basic EPS | 55.38% | 62.29% | 36.76% | -20.44% | -104.79% |
| EPS Diluted | 70.80% | 66.44% | 36.89% | -11.07% | -17.46% |
| Normalized Diluted EPS | 55.38% | 62.29% | 36.76% | -20.44% | -104.79% |
| Average Basic Shares Outstanding | 93.35% | 314.16% | 371.15% | 305.74% | 227.25% |
| Average Diluted Shares Outstanding | 93.35% | 314.16% | 371.15% | 305.74% | 227.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |